These cases provide early but encouraging evidence that IL-23 inhibitors might serve as effective and well-tolerated options in patients with overlapping autoimmune conditions, including those with atypical or treatment-resistant forms of pemphigoid [59]. Here, IL23A is linked to autoimmune bullous skin disease.